Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
Febbo P, Richie J, George D, Loda M, Manola J, Shankar S, Barnes A, Tempany C, Catalona W, Kantoff P, Oh W. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research 2005, 11: 5233-5240. PMID: 16033841, DOI: 10.1158/1078-0432.ccr-05-0299.Peer-Reviewed Original ResearchConceptsEndorectal magnetic resonance imagingHigh-risk localized prostate cancerProstate-specific antigen declinePathological complete responseLocalized prostate cancerMagnetic resonance imagingRadical prostatectomyNeoadjuvant docetaxelComplete responseProstate cancerSerum prostate-specific antigen measurementSerum prostate-specific antigen levelClinical stage T3 diseaseMaximum tumor volume reductionNo pathologic complete responsesProstate-specific antigen levelProstate-specific antigen measurementNeoadjuvant docetaxel chemotherapyStage T3 diseaseBiopsy Gleason scoreTumor volume reductionProstate-specific antigenResponse to chemotherapyDecreased tumor volumeFrozen tumor specimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply